PLI Pharma Rs 15,000 Crore: Eligibility, Incremental Sales, Disbursement

A biosimilars-focused Tier 2 pharmaceutical applicant of the scale of Biocon Biologics — the Biocon Ltd subsidiary operating out of the Bommasandra campus in Bengaluru and the Malaysia insulin campus — closes its Year 4 quarterly claim on the Department of Pharmaceuticals PLI Pharma portal for the September 2024 quarter with three DoP-approved identified products (biosimilar-Trastuzumab, biosimilar-Rituximab, biosimilar-Bevacizumab), an FY 2019-20 DoP-approved base sales register of approximately Rs 350 crore (illustrative), cumulative Year 4 incremental sales approaching Rs 1,600 crore against a DoP-set Year 4 threshold of Rs 800 crore (a 200 percent-of-threshold performance), and a Category 1 incentive rate of 10 percent of eligible incremental sales capped at Rs 100 crore per applicant per year. This is PLI pharma Rs 15,000 crore eligibility incremental sales reconciliation at operating scale for a Category 1 major applicant, and the discipline that keeps the DoP portal quarterly claim, the Ind AS 20 grant recognition, the Section 115JB MAT book-profit adjustment, and the Section 92BA specified-domestic-transaction register simultaneously clean is what separates an applicant whose year-end disbursement runs on schedule from one that spends the following financial year litigating a mis-mapped identified product or a Section 74 exposure on an intra-group biosimilar transfer.

Quick reference

The reconciliation in one paragraph

A Category 1 PLI Pharma applicant runs a four-surface reconciliation cascade across the DoP scheme window. Surface one is the FY 2019-20 base sales register — the identified products, their DoP-approved base sales value per product, and the ERP material-code mapping that ties each base value to a live SAP or Oracle sales ledger stream. Surface two is the year-and-quarter incremental sales bridge — the quarter’s identified-product sales from the ERP ledger minus the allocated base for the quarter (typically one-quarter of the annual DoP-approved base), aggregated year-to-date and tested against the DoP-published year threshold to confirm eligibility. Surface three is the incentive computation and cap binding — the Category 1 rate schedule (10 percent Years 1 to 4, 8 percent Year 5, 6 percent Year 6) applied to the eligible incremental sales, then capped at Rs 100 crore per applicant per year with the excess raw incentive explicitly quantified as foregone. Surface four is the accounting and tax overlay — Ind AS 20 recognition of the PLI grant receivable as it becomes reasonably assured, presentation choice between other income and net-of-expense, Section 115JB MAT book-profit adjustment on the grant income, and Section 92BA transfer-pricing documentation on any intra-group transfer of identified products. Each surface is a distinct reconciliation and each carries its own DoP portal, statutory auditor, and internal audit exposure.

What the scenario looks like in India — the illustrative persona

The PLI Pharma Rs 15,000 crore scheme has a defined applicant universe across the three categories. Category 1 is the applicant pool for complex-formulation manufacturers and biosimilars developers — the umbrella that includes biosimilars-focused subsidiaries (Biocon Biologics, the subsidiary of Biocon Ltd operating from Bommasandra), integrated formulators with a complex-generics pipeline (Sun Pharmaceutical Industries with its Halol Gujarat and Dadra plants, Dr Reddy’s Laboratories with its Hyderabad and Bachupally campuses, Cipla with its Goa and Verna plants, Lupin with its Aurangabad and Ankleshwar plants, Aurobindo Pharma with its Hyderabad campus, Zydus Lifesciences with its Ahmedabad and Vadodara campuses), and speciality players such as Piramal Pharma and Torrent Pharmaceuticals. Category 2 is the API-and-KSM applicant pool that overlaps partially with the separate PLI Bulk Drug Rs 6,940 crore scheme envelope — Divi’s Laboratories (with the Bollaram and Vishakhapatnam API campuses), Neuland Laboratories, Laurus Labs, Suven Pharmaceuticals, and the API subsidiaries of the integrated formulators (Aurobindo APL, Dr Reddy’s API division). Category 3 is the diagnostics-and-devices applicant pool — Poly Medicure for medical devices, Wockhardt straddling formulation and device manufacture, and Cadila Pharmaceuticals for repurposed-drug candidates.

For the illustrative worked example in this article, we take a Category 1 applicant at the scale of a Tier 2 biosimilars developer — the Biocon Biologics persona for a Category 1 applicant with an FY 2019-20 base of Rs 350 crore across three identified biosimilar molecules. The persona is illustrative; real PLI Pharma applicant lists, scheme applications, and DoP-approved base values are disclosed in aggregate by the Department of Pharmaceuticals and are not the subject of speculative recomputation here. The point of the persona is the reconciliation surface, not the identity of any specific real applicant.

The regional pharma manufacturing geography maps to specific plant regions: Baddi in Himachal Pradesh (the excise-legacy formulation cluster), Sikkim (the Section 80-IE legacy cluster), Ahmedabad-Vadodara (Gujarat integrated pharma), Hyderabad-Bachupally-Bollaram (Telangana and AP API-and-formulation cluster), Mumbai-Thane (Maharashtra formulation), Halol (Gujarat), Kurkumbh (Maharashtra), Verna (Goa), Ankleshwar (Gujarat), and Bengaluru (Karnataka biosimilars and specialty). A PLI Pharma applicant with multi-state manufacturing footprint must consolidate the identified-product sales across state GSTINs, apply the material-code mapping consistently across every plant, and reconcile the DoP portal claim against the aggregated ERP ledger extract — not against a single state-GSTIN filing.

The regulatory overlay — DoP scheme guidelines, Ind AS 20, Section 115JB MAT, Section 115BAA, Section 92BA

Five regulatory anchors govern the PLI Pharma claim and disbursement chain, and each maps to a specific reconciliation surface.

The PLI Pharma scheme guidelines are notified by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers with a total outlay of Rs 15,000 crore across six financial years. Base year is FY 2019-20; incentive window is FY 2020-21 (Year 1) to FY 2025-26 (Year 6). The three categories carry distinct eligibility criteria — minimum threshold investment during the scheme window, minimum incremental sales as a percentage of the base for Year 1 to establish continued participation, minimum R&D expenditure floor, and (for Category 3 medical devices) minimum export commitment. Category 1 requires a minimum Year 1 incremental sales of 10 percent of the base to establish participation. The incentive rate schedule for Category 1 is 10 percent of eligible incremental sales for Years 1 through 4, 8 percent in Year 5, and 6 percent in Year 6, capped at Rs 100 crore per applicant per year. Category 2 and Category 3 have separately published rate schedules and caps. Quarterly claim submission is filed on the DoP PLI portal, supported by a statutory auditor certificate; the review cycle typically produces an approval, a query letter, or a partial disbursement decision within 60 to 90 days.

Ind AS 20 (Accounting for Government Grants and Disclosure of Government Assistance), notified by the Ministry of Corporate Affairs as part of the Companies (Indian Accounting Standards) Rules 2015 and subsequent amendments, governs the recognition and presentation of the PLI grant. Grants related to income (as distinct from grants related to assets) are recognised in profit or loss on a systematic basis over the periods in which the entity recognises as expenses the related costs for which the grants are intended to compensate. The PLI grant is a grant related to income — it compensates the applicant for the incremental production and sale during the scheme window, not for a specific asset acquisition. The grant receivable is recognised when the applicant has reasonable assurance that it will comply with the scheme conditions and that the grant will be received. The presentation choice permitted by Ind AS 20 is to either recognise the grant as other income on a separate line, or net it against the related expense line. Terra Insight’s Reconciliation Playbook monthly close framework treats the grant recognition as a specific month-end control point that must be documented in the entity’s accounting policy note.

Section 115JB of the Income-tax Act 1961 imposes Minimum Alternate Tax at 15 percent of book profit (plus applicable surcharge and cess) where the tax computed under normal provisions is lower. Book profit is the profit as per the profit and loss statement, adjusted upward or downward by the specific items listed in Explanation 1 to Section 115JB. The PLI grant income is not currently listed as an exempt item that reduces book profit; the grant increases book profit and correspondingly the MAT base. An applicant that has opted into the Section 115BAA concessional 22 percent regime is exempt from Section 115JB MAT altogether — but Section 115BAA also restricts the applicant from claiming specified incentives including the Section 35(2AB) R&D weighted deduction, which is materially valuable to a biosimilars developer with a DSIR-approved R&D facility spending on Phase III bioequivalence trials. The trade-off between staying under the normal regime (with MAT exposure on the PLI grant income but continued access to Section 35(2AB) weighted deduction under the pharma R&D reconciliation guide) versus opting into Section 115BAA (no MAT but forfeiture of Section 35(2AB)) is a modelling input at scheme entry and must be re-evaluated as the R&D expenditure and PLI incremental sales trajectories become clearer.

Section 92BA of the Income-tax Act 1961 requires Rule 10D transfer-pricing documentation for specified domestic transactions between associated enterprises resident in India where the aggregate value exceeds the notified threshold in a year. A pharmaceutical applicant with backward-integration API transfer from its own API subsidiary to its formulation plant — a Category 1 applicant with a Category 2 API subsidiary in the same corporate group — must document the intra-group API transfer price under Rule 10D. The PLI incremental-sales computation must include or exclude intra-group transactions depending on the scheme’s definition of eligible sales. Typically, arm’s-length third-party sales are counted in incremental sales; intra-group transfers priced at cost or at a captive-consumption benchmark may be excluded or partially included depending on the DoP scheme rules for the specific category. The reconciliation must expose the intra-group transfer volume, the Rule 10D transfer-pricing documentation reference, and the DoP scheme treatment applied — this discipline is elaborated in the API vs formulation HSN 2941 / 3003 / 3004 reconciliation guide for the backward-integration API transfer case.

A worked example — a Category 1 biosimilars applicant at Year 4 quarterly close

Illustrative — the following figures represent the operating pattern of a Category 1 PLI Pharma applicant of the scale of a Tier 2 biosimilars developer. Public disclosures do not reveal per-product DoP-approved base sales values or per-quarter incremental sales bridges; the numbers below are illustrative of the reconciliation surface, not a claim about any specific real applicant’s PLI position.

A Category 1 biosimilars applicant enters the scheme with three DoP-approved identified products for FY 2019-20 base: biosimilar-Trastuzumab (base value Rs 140 crore), biosimilar-Rituximab (base value Rs 120 crore), and biosimilar-Bevacizumab (base value Rs 90 crore). Aggregate base is Rs 350 crore. The applicant’s Year 1 (FY 2020-21) identified-product sales come in at Rs 420 crore, delivering incremental sales of Rs 70 crore — a 20 percent uplift over base, comfortably clearing the 10 percent minimum incremental sales requirement for Category 1 continued participation. The Year 1 incentive at 10 percent of Rs 70 crore is Rs 7 crore, well below the Rs 100 crore Category 1 per-applicant per-year cap.

Year 2 (FY 2021-22) identified-product sales rise to Rs 680 crore on the biosimilars ramp — incremental of Rs 330 crore, incentive at 10 percent = Rs 33 crore. Year 3 (FY 2022-23) sales reach Rs 1,050 crore — incremental of Rs 700 crore, raw incentive at 10 percent = Rs 70 crore. Year 4 (FY 2023-24) sales cumulate to Rs 1,950 crore across identified products — incremental of Rs 1,600 crore against the base, against a DoP-published Year 4 threshold of Rs 800 crore that the applicant clears at 200 percent-of-threshold. The raw incentive at 10 percent of Rs 1,600 crore is Rs 160 crore. The Category 1 per-applicant per-year cap of Rs 100 crore binds; the eligible incentive claim for Year 4 is Rs 100 crore and the Rs 60 crore excess walks away — it does not roll forward to Year 5 or backward to Year 3 unused capacity.

The Year 4 quarterly claim workbook filed on the DoP PLI portal for the September 2024 quarter (Q2 FY 2023-24) shows:

On the accounting side, the Q2 PLI grant receivable of Rs 75 crore is recognised under Ind AS 20 (grant related to income) as reasonable assurance is established through the DoP portal filing and statutory auditor certificate; the applicant presents the grant as other income on the profit and loss statement per its accounting policy choice. Section 115JB MAT book-profit adjustment adds the Rs 75 crore grant to book profit for the quarter’s MAT provisioning; the applicant is under the normal tax regime (not Section 115BAA) because the biosimilars R&D pipeline continues to attract Section 35(2AB) weighted deduction that Section 115BAA would forfeit. The DoP portal review cycle for the Q2 filing produces approval within 75 days and the disbursement of Rs 75 crore is credited to the applicant’s designated bank account, matched against the receivable on ledger.

Aggregating across the six-year window: Year 1 Rs 7 crore + Year 2 Rs 33 crore + Year 3 Rs 70 crore + Year 4 Rs 100 crore (capped) + Year 5 at 8 percent capped + Year 6 at 6 percent capped can approach a cumulative Rs 400 to Rs 500 crore over the scheme window for a Category 1 major applicant of this scale — the exact number depends on the year-by-year incremental sales trajectory and the year-by-year cap binding.

Common reconciliation breakages

Five breakages recur across PLI Pharma Category 1 claim runs, and each maps to a specific control failure.

• ERP product-code to DoP identified-product mis-mapping. The applicant launches a new SKU in the ERP material master under a naming convention that is close to but not identical to the DoP-approved identified-product code. The quarterly claim workbook extract keys on the DoP list and misses the new SKU sales; the incremental sales computation understates by the missed SKU volume, and the eligible incentive is short-claimed. The mis-mapping surfaces at the statutory auditor certificate cycle when the auditor cross-checks the ERP sales report against the claim workbook line-by-line. Reconciliation discipline requires that the ERP material master is fenced with a DoP identified-product flag, and any new SKU launch triggers a fresh DoP notification workflow before the SKU can be included in the claim.

• Export sales inclusion or exclusion error. The PLI Pharma scheme rules on inclusion of export sales in eligible incremental sales vary by category and by product type. Some Category 1 applicants include export sales in eligible incremental sales; some exclude them. Applicants that apply the wrong rule — including exports that should be excluded — over-claim the incentive and expose themselves to a Section 74 GST or Section 271 income-tax demand at the DoP audit or the statutory audit cycle. The reconciliation surface is a separate export-sales ledger within the identified-product sales register, clearly tagged and reconciled against the DGFT shipping-bill register with the RoDTEP and drawback stack, and applied to the claim workbook per the DoP scheme rule for that category.

• Sample and free-goods distribution wrongly included in incremental sales. Physician sample distribution, free-goods rebate issuances, and clinical-trial supply are typically not booked as revenue in the applicant’s ERP; they carry a zero-value invoice or a distinct GL account. Where the claim workbook extract keys only on physical dispatch quantity, sample volumes get included in identified-product sales and inflate incremental sales. The applicant must filter sample and free-goods invoices out of the claim workbook at extraction, document the exclusion, and reconcile to the ERP GL account balance for sample distribution.

• Section 92BA intra-group transfer treatment gap. A Category 1 applicant with backward-integration API supply from its own Category 2 API subsidiary treats the intra-group API transfer under Rule 10D transfer-pricing documentation. The PLI incremental-sales computation must apply the scheme’s rule on intra-group transactions — typically eligible sales are arm’s-length third-party sales, and intra-group transfers at a captive-consumption benchmark may be excluded. Applicants that include the intra-group transfer volume in incremental sales without applying the scheme rule over-claim the incentive; applicants that exclude intra-group transfers where the scheme permits inclusion under-claim. Reconciliation discipline requires the Section 92BA specified-domestic-transaction register to feed the claim workbook exclusion or inclusion decision, with the DoP scheme rule cited on each line.

• Ind AS 20 grant recognition timing and Section 115JB MAT under-provisioning. Applicants that recognise the PLI grant receivable only on cash receipt (rather than when reasonable assurance is established through the DoP portal approval) create a book-tax timing gap and can under-provision Section 115JB MAT for the period in which the grant is earned but not received. The reconciliation discipline is that the DoP portal approval letter triggers the Ind AS 20 grant receivable recognition, the same period triggers the Section 115JB MAT book-profit adjustment, and the cash-receipt event only settles the receivable balance without a fresh income event. Terra Insight’s reconciliation failure-mode analysis for India methodology treats the grant-recognition timing as a specific failure mode with a documented control test.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the DoP-approved identified-product master, the applicant’s SAP FI or Oracle Fusion sales ledger extract by material code, the Section 92BA intra-group transfer register, the DGFT export shipping-bill register, and the ERP sample-and-free-goods GL account — and produces a per-quarter identified-product incremental sales bridge that closes the loop from ERP invoice line to DoP portal claim workbook. The platform applies the DoP-published incremental sales threshold for the year, computes the Category-appropriate incentive rate against eligible incremental sales, binds the applicant-year cap and explicitly quantifies the excess incentive foregone, generates the DoP portal quarterly claim workbook and the statutory auditor certificate template, and drives the Ind AS 20 grant receivable recognition entry with the Section 115JB MAT book-profit adjustment line into the entity’s tax provisioning workflow. Match rate improvement of 51 to 88 percent on the identified-product sales extraction and the quarterly claim workbook reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Category 1 major applicant or a Category 2 API supplier running a multi-scheme PLI claim stack rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The PLI Pharma discipline in this cornerstone sits alongside the Rule 89(5) inverted-duty refund cycle that a pharma formulator runs against the 5 percent output on drugs versus the 18 percent input on APIs and packaging — the mechanic is unpacked in the rule 89(5) inverted-duty refund pharma formulations complete guide alongside its cross-cluster analogues in the dairy inverted-duty refund under Rule 89(5) post GST 2.0 and the CBIC Notification 09/2022 blocking mechanic in the edible oil Chapter 15 IDR refund blocked walkthrough. The R&D weighted-deduction interaction that governs the Section 115BAA versus Section 35(2AB) trade-off for a Category 1 biosimilars applicant is elaborated in the Section 35(2AB) weighted deduction pharma R&D reconciliation guide. The loan-licensee contract-manufacturing model that determines who is the applicant when Category 1 formulation is manufactured by a third-party CDMO is walked through in the loan-licensing manufacturing and pharma CDMO reconciliation guide. The methodology framework for structuring the quarterly claim as a controlled reconciliation surface is set out in Terra Insight’s reconciliation playbook monthly close pillar. The commercial pillar for the entire pharma sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India.

The five FAQs below address the operational questions pharma controllers and PLI scheme compliance leads ask most often when running the Category 1 quarterly claim workbook against the DoP portal.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 13 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024